8-K: Cardiff Oncology Reports Q1 2026 Results, Advances Phase 3 Trial

Cardiff Oncology announced first quarter 2026 financial results, highlighting a successful End-of-Phase 2 meeting with the FDA for its onvansertib Phase 3 trial and updated clinical data presentations.

Summary

• Cardiff Oncology reported its first quarter 2026 financial results and provided a business update.
• The company completed a successful End-of-Phase 2 meeting with the FDA, aligning on key design elements for the Phase 3 registrational trial of onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC).
• Updated data from the Phase 2 CRDF-004 trial will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
• The company appointed new leadership, including a CEO, CFO, and COO, to support upcoming milestones.
• As of March 31, 2026, Cardiff Oncology had approximately $46.1 million in cash, cash equivalents, and short-term investments.
• Net cash used in operating activities for Q1 2026 was approximately $12.3 million.
• Total operating expenses for Q1 2026 were approximately $12.9 million, a decrease from the prior year.
• The company believes its current cash resources are sufficient to fund operations into the first quarter of 2027.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report due to significant clinical data improvements, successful FDA engagement for the Phase 3 trial, and strengthened leadership, despite ongoing net losses typical for clinical-stage biotech.

Positives

• Successful End-of-Phase 2 meeting with the FDA, with alignment on key design elements for the Phase 3 registrational trial.
• Selected the 30 mg dose of onvansertib for the Phase 3 trial in combination with FOLFIRI/bev chemotherapy regimen.
• Phase 2 CRDF-004 trial showed a 72.2% objective response rate (ORR) with 30 mg onvansertib + FOLFIRI/bevacizumab arm, compared to 43.2% for standard-of-care arms.
• Demonstrated marked improvement in progression-free survival (PFS) with onvansertib combination (HR: 0.38 vs FOLFIRI/bev, HR: 0.37 vs combined SoC), with no significant added toxicity.
• New preclinical data presented at AACR showed onvansertib enhanced the activity of trastuzumab deruxtecan (T-DXd) in HER2-low breast cancer models.
• Strengthened leadership team with appointments of Mani Mohindru as CEO, Josh Muntner as CFO, and Ajay Aggarwal as COO.
• Net cash used in operating activities decreased by approximately $0.5 million compared to the same period in 2025.
• Total operating expenses decreased by $1.6 million compared to the same period in 2025, primarily due to lower R&D expenses.

Negatives

• Net loss of $12.3 million for the first quarter of 2026.
• Net loss per common share was $0.18 for the first quarter of 2026.
• Royalty revenues decreased to $41 thousand from $109 thousand in the prior year period.
• Selling, general and administrative (SG&A) expenses increased by $2.1 million, primarily due to employee severance agreements.
• Cash and cash equivalents decreased from $17.47 million at December 31, 2025, to $8.54 million at March 31, 2026.
• Short-term investments decreased from $40.83 million at December 31, 2025, to $37.51 million at March 31, 2026.
• Total current assets decreased from $60.13 million at December 31, 2025, to $47.34 million at March 31, 2026.
• Total assets decreased from $61.88 million at December 31, 2025, to $49.17 million at March 31, 2026.

Risks

• Clinical trials involve a lengthy and expensive process with an uncertain outcome.
• Results of earlier studies and trials may not be predictive of future trial results.
• Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks.
• Results of preclinical studies or clinical trials could be unfavorable or delayed.
• Need for additional financing.
• Risks related to business interruptions, including cyber-attacks.
• Uncertainties of government or third-party payer reimbursement.
• Dependence on key personnel and substantial competition.

Future Outlook

The company believes its current cash resources are sufficient to fund its operations into the first quarter of 2027. Additional details of the Phase 3 clinical trial will be shared by mid-2026, along with the regulatory strategy.

Management Comments

• "This quarter was marked by the positive data update from our randomized Phase 2 CRDF-004 trial of onvansertib in first-line RAS-mutated metastatic colorectal cancer, along with key leadership additions that prepare the Company to deliver on the clinical milestones ahead," said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology.
• "In April, we had a successful End-of-Phase 2 meeting with the FDA and aligned on the key design elements for our Phase 3 registrational trial. We plan to share additional Phase 3 details and our regulatory strategy in mid-2026."
• "At the upcoming ASCO Annual Meeting, we will present updated CRDF-004 data, which we believe will provide further insight into onvansertib's potential in the first-line RAS-mutated metastatic colorectal cancer (mCRC) setting."
• "With strong clinical momentum, we remain focused on disciplined execution throughout the year."

Industry Context

StockSavvy.ai notes that Cardiff Oncology's progress with onvansertib in first-line RAS-mutated mCRC aligns with the industry trend of developing targeted therapies for specific genetic mutations in cancer, aiming to improve efficacy and reduce toxicity compared to broad-spectrum chemotherapy.

Comparison to Industry Standards

• The reported ORR of 72.2% for onvansertib + FOLFIRI/bev in first-line RAS-mutated mCRC significantly exceeds historical ORRs for standard-of-care chemotherapy regimens in this patient population, which typically range from 30-50%.
• The PFS hazard ratio of 0.37-0.38 indicates a substantial reduction in the risk of disease progression compared to standard-of-care, a critical metric in oncology drug development.
• The company's focus on PLK1 inhibition is a specialized area within oncology drug development, with other companies also exploring this pathway, though onvansertib appears to be a leading candidate in its specific indication.
• The successful End-of-Phase 2 meeting with the FDA suggests a clear regulatory pathway, which is a positive indicator compared to companies facing significant hurdles in their discussions with regulatory bodies.

Management Changes

Stakeholder Impact

• Shareholders: Positive clinical data and FDA alignment for Phase 3 trial could lead to increased valuation, but ongoing net losses and cash burn remain a concern.
• Employees: New leadership appointments signal a focus on execution and growth, potentially creating a more stable and dynamic work environment.
• Creditors: The company's cash runway into Q1 2027 suggests short-term solvency, reducing immediate concerns for creditors.
• Suppliers: Continued operations and clinical trial progression will maintain demand for services and materials.

Next Steps

• Present updated CRDF-004 data at the ASCO Annual Meeting 2026.
• Share additional Phase 3 details and regulatory strategy by mid-2026.
• Initiate the Phase 3 registrational trial in patients with first-line RAS-mutated mCRC.
• Continue to strengthen the scientific foundation of the PLK1 inhibition strategy with preclinical and investigator-initiated studies.

Key Dates

Recommendation

Cardiff Oncology presents compelling clinical data and a clear regulatory path for its lead asset, onvansertib, which is a significant positive. However, the company continues to operate at a net loss, and its cash runway, while extending into early 2027, requires careful monitoring. The upcoming Phase 3 trial will be critical and expensive. Therefore, a 'hold' recommendation is appropriate, awaiting further data and de-risking of the Phase 3 execution and financing needs.

Keywords

Cardiff Oncology, onvansertib, metastatic colorectal cancer, mCRC, Phase 3 trial, FDA, ASCO, PLK1 inhibition